Mineralys Therapeutics Inc [MLYS] stock prices are up 2.44% to $41.12 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MLYS shares have gain 0.76% over the last week, with a monthly amount glided 3.29%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mineralys Therapeutics Inc [NASDAQ: MLYS] stock has seen the most recent analyst activity on June 11, 2025, when Jefferies initiated its Hold rating and assigned the stock a price target of $15. Previously, H.C. Wainwright started tracking the stock with Buy rating on July 10, 2024, and set its price target to $30. On April 02, 2024, Goldman initiated with a Buy rating and assigned a price target of $30 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $27 on March 07, 2023. Stifel initiated its recommendation with a Buy and recommended $45 as its price target on March 07, 2023. Guggenheim started tracking with a Buy rating for this stock on March 07, 2023, and assigned it a price target of $32. In a note dated March 07, 2023, Evercore ISI initiated an Outperform rating.
The stock price of Mineralys Therapeutics Inc [MLYS] has been fluctuating between $8.24 and $44.80 over the past year. Currently, Wall Street analysts expect the stock to reach $50 within the next 12 months. Mineralys Therapeutics Inc [NASDAQ: MLYS] shares were valued at $41.12 at the most recent close of the market. An investor can expect a potential return of 21.6% based on the average MLYS price forecast.
Analyzing the MLYS fundamentals
Gross Profit Margin for this corporation currently stands at -0.26% with Operating Profit Margin at -5972.53%, Pretax Profit Margin comes in at -5610.97%, and Net Profit Margin reading is -5610.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -0.7 and Total Capital is -0.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 39.94 points at the first support level, and at 38.76 for the second support level. However, for the 1st resistance point, the stock is sitting at 42.87, and for the 2nd resistance point, it is at 44.61.
Ratios To Look Out For
It’s worth pointing out that Mineralys Therapeutics Inc [NASDAQ:MLYS]’s Current Ratio is 15.12. As well, the Quick Ratio is 15.12, while the Cash Ratio is 4.59.
Transactions by insiders
Recent insider trading involved Levy Adam Scott, CFO and Secretary, that happened on Oct 13 ’25 when 10758.0 shares were sold. Chief Executive Officer, Congleton Jon completed a deal on Oct 13 ’25 to sell 15100.0 shares. Meanwhile, Chief Medical Officer Rodman David Malcom sold 10369.0 shares on Oct 15 ’25.
